Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of two dose levels of ONO-4578 with nivolumab, plus mFOLFOX6 and bevacizumab, versus standard of care in PD-L1 positive, non-MSI-H/dMMR advanced c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MFOLFOX6
• ONO-4578
• OPDIVO (nivolumab)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Colorectal Cancer | Phase 2 | Status: RECRUITING